← Nektar Therapeutics overview

Nektar Therapeutics vs Precigen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Nektar Therapeutics (NKTR)

Q3 2026
▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

  • Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.

    It is the period's first hard financial update and sets the baseline for how investors judge the company.

  • Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.

    It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.

  • Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.

    It captures the market's fear during the trial, the main event driving NKTR this period.

  • Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.

    It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

September 2026
▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

  • Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.

    It is the period's first hard financial update and sets the baseline for how investors judge the company.

  • Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.

    It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.

  • Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.

    It captures the market's fear during the trial, the main event driving NKTR this period.

  • Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.

    It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

Latest
▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

  • Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.

    It is the period's first hard financial update and sets the baseline for how investors judge the company.

  • Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.

    It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.

  • Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.

    It captures the market's fear during the trial, the main event driving NKTR this period.

  • Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.

    It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

Precigen Inc (PGEN)

Q3 2026
▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

  • Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.

    The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.

  • Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.

    This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.

  • FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.

    The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.

  • Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.

    This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

August 2026
▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

  • Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.

    The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.

  • Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.

    This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.

  • FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.

    The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.

  • Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.

    This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

Latest
▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

  • Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.

    The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.

  • Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.

    This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.

  • FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.

    The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.

  • Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.

    This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.